1.
|
Ponce RA, Gelzleichter T, Haggerty HG, et
al: Immunomodulation and lymphoma in humans. J Immunotoxicol. Jun
7–2013.(Epub ahead of print).
|
2.
|
Ghosh SK, Perrine SP, Williams RM and
Faller DV: Histone deacetylase inhibitors are potent inducers of
gene expression in latent EBV and sensitize lymphoma cells to
nucleoside antiviral agents. Blood. 119:1008–1017. 2012. View Article : Google Scholar
|
3.
|
Brocqueville G, Ndour PA, Ouk TS, et al:
LMP1-induced cell death may contribute to the emergency of its
oncogenic property. PLoS One. 8:e607432013. View Article : Google Scholar : PubMed/NCBI
|
4.
|
Smuk G, Illes A, Keresztes K, et al:
Pheno- and genotypic features of Epstein-Barr virus associated
B-cell lymphoproliferations in peripheral T-cell lymphomas. Pathol
Oncol Res. 16:377–383. 2010. View Article : Google Scholar : PubMed/NCBI
|
5.
|
Diduk SV, Smirnova KV, Pavlish OA and
Gurtsevitch VE: Functionally significant mutations in the
Epstein-Barr virus LMP1 gene and their role in activation of cell
signaling pathways. Biochemistry (Mosc). 73:1134–1139. 2008.
View Article : Google Scholar : PubMed/NCBI
|
6.
|
Everly DN Jr, Mainou BA and Raab-Traub N:
The ID proteins contribute to the growth of rodent fibroblasts
during LMP1-mediated transformation. Virology. 376:258–269. 2008.
View Article : Google Scholar : PubMed/NCBI
|
7.
|
Wu ZZ, Chow KP, Kuo TC, Chang YS and Chao
CC: Latent membrane protein 1 of Epstein-Barr virus sensitizes
cancer cells to cisplatin by enhancing NF-kappaB p50 homodimer
formation and downregulating NAPA expression. Biochem Pharmacol.
82:1860–1872. 2011. View Article : Google Scholar : PubMed/NCBI
|
8.
|
Lu JH, Tang YL, Yu HB, et al: Epstein-Barr
virus facilitates the malignant potential of immortalized
epithelial cells: from latent genome to viral production and
maintenance. Lab Invest. 90:196–209. 2010. View Article : Google Scholar : PubMed/NCBI
|
9.
|
Gan R, Xie X, He J, et al: Gene analysis
of Epstein-Barr virus-associated lymphomas in Hu-Pbl/SCID chimeras.
Tumori. 96:465–472. 2010.PubMed/NCBI
|
10.
|
Arcipowski KM and Bishop GA: TRAF binding
is required for a distinct subset of in vivo B cell functions of
the oncoprotein LMP1. J Immunol. 189:5165–5170. 2012. View Article : Google Scholar : PubMed/NCBI
|
11.
|
Yoshizaki T, Kondo S, Wakisaka N, et al:
Pathogenic role of Epstein-Barr virus latent membrane protein-1 in
the development of nasopharyngeal carcinoma. Cancer Lett. 337:1–7.
2013. View Article : Google Scholar : PubMed/NCBI
|
12.
|
Zheng H, Li LL, Hu DS, Deng XY and Cao Y:
Role of Epstein-Barr virus encoded latent membrane protein 1 in the
carcinogenesis of nasopharyngeal carcinoma. Cell Mol Immunol.
4:185–196. 2007.PubMed/NCBI
|
13.
|
Tao YG, Tan YN, Liu YP, et al:
Epstein-Barr virus latent membrane protein 1 modulates epidermal
growth factor receptor promoter activity in a nuclear factor kappa
B-dependent manner. Cell Signal. 16:781–790. 2004. View Article : Google Scholar
|
14.
|
Wang Z, Luo F, Li L, et al: STAT3
activation induced by Epstein-Barr virus latent membrane protein1
causes vascular endothelial growth factor expression and cellular
invasiveness via JAK3 And ERK signaling. Eur J Cancer.
46:2996–3006. 2010. View Article : Google Scholar
|
15.
|
Horikawa T, Yang J, Kondo S, et al: Twist
and epithelial-mesenchymal transition are induced by the EBV
oncoprotein latent membrane protein 1 and are associated with
metastatic nasopharyngeal carcinoma. Cancer Res. 67:1970–1978.
2007. View Article : Google Scholar
|
16.
|
Dawson CW, Laverick L, Morris MA,
Tramoutanis G and Young LS: Epstein-Barr virus-encoded LMP1
regulates epithelial cell motility and invasion via the ERK-MAPK
pathway. J Virol. 82:3654–3664. 2008. View Article : Google Scholar : PubMed/NCBI
|
17.
|
Sheu LF, Chen A, Wei YH, et al:
Epstein-Barr virus LMP1 modulates the malignant potential of
gastric carcinoma cells involving apoptosis. Am J Pathol.
152:63–74. 1998.PubMed/NCBI
|
18.
|
Li G, Li XP, Peng Y, Liu X and Li XH:
Effect of inhibition of EBV-encoded latent membrane protein-1 by
small interfering RNA on EBV-positive nasopharyngeal carcinoma cell
growth. Di Yi Jun Yi Da Xue Xue Bao. 24:241–246. 2004.PubMed/NCBI
|
19.
|
Li XP, Li G, Peng Y, Kung HF and Lin MC:
Suppression of Epstein-Barr virus-encoded latent membrane protein-1
by RNA interference inhibits the metastatic potential of
nasopharyngeal carcinoma cells. Biochem Biophys Res Commun.
315:212–218. 2004. View Article : Google Scholar
|
20.
|
Ndour PA, Brocqueville G, Ouk TS, et al:
Inhibition of latent membrane protein 1 impairs the growth and
tumorigenesis of latency II Epstein-Barr virus-transformed T cells.
J Virol. 86:3934–3943. 2012. View Article : Google Scholar : PubMed/NCBI
|
21.
|
Yang L, Lu Z, Ma X, Cao Y and Sun LQ: A
therapeutic approach to nasopharyngeal carcinomas by DNAzymes
targeting EBV LMP-1 gene. Molecules. 15:6127–6139. 2010. View Article : Google Scholar : PubMed/NCBI
|
22.
|
Lu ZX, Ma XQ, Yang LF, et al: DNAzymes
targeted to EBV-encoded latent membrane protein-1 induce apoptosis
and enhance radiosensitivity in nasopharyngeal carcinoma. Cancer
Lett. 265:226–238. 2008. View Article : Google Scholar : PubMed/NCBI
|
23.
|
Glaser R, Zhang HY, Yao KT, et al: Two
epithelial tumor cell lines (HNE-1 and HONE-1) latently infected
with Epstein-Barr virus that were derived from nasopharyngeal
carcinomas. Proc Natl Acad Sci USA. 86:9524–9528. 1989. View Article : Google Scholar : PubMed/NCBI
|
24.
|
Zhao Y, Tao YG, Luo FJ, Tang FQ, Tang M
and Cao Y: Interference effect of epigallocatechin-3-gallate on
targets of nuclear factor kappaB signal transduction pathways
activated by EB virus encoded latent membrane protein 1. Int J
Biochem Cell Biol. 36:1473–1481. 2004.
|
25.
|
Benimetskaya L, Takle GB, Vilenchik M,
Lebedeva I, Miller P and Stein CA: Cationic porphyrins: novel
delivery vehicles for antisense oligodeoxynucleotides. Nucleic
Acids Res. 26:5310–5317. 1998. View Article : Google Scholar : PubMed/NCBI
|
26.
|
Lu ZX, Ye M, Yan GR, et al: Effect of EBV
LMP1 targeted DNAzymes on cell proliferation and apoptosis. Cancer
Gene Ther. 12:647–654. 2005. View Article : Google Scholar : PubMed/NCBI
|
27.
|
Sugimoto M, Martin N, Wilks DP, et al:
Activation of cyclin D1-kinase in murine fibroblasts lacking both
p21(Cip1) and p27(Kip1). Oncogene. 21:8067–8074. 2002. View Article : Google Scholar : PubMed/NCBI
|
28.
|
Ling S and Lin WC: EDD inhibits
ATM-mediated phosphorylation of p53. J Biol Chem. 286:14972–14982.
2011. View Article : Google Scholar : PubMed/NCBI
|
29.
|
Kitagawa M, Higashi H, Jung HK, et al: The
consensus motif for phosphorylation by cyclin D1-Cdk4 is different
from that for phosphorylation by cyclin A/E-Cdk2. EMBO J.
15:7060–7069. 1996.PubMed/NCBI
|
30.
|
Hansen U, Owens L and Saxena UH:
Transcription factors LSF and E2Fs: tandem cyclists driving G0 to
S? Cell Cycle. 8:2146–2151. 2009. View Article : Google Scholar : PubMed/NCBI
|
31.
|
Zhang XH, Zou ZQ, Xu CW, Shen YZ and Li D:
Myricetin induces G2/M phase arrest in HepG2 cells by inhibiting
the activity of the cyclin B/Cdc2 complex. Mol Med Rep. 4:273–277.
2011.PubMed/NCBI
|
32.
|
Tan M, Jing T, Lan KH, et al:
Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits
p34(Cdc2) activation and is involved in resistance to taxol-induced
apoptosis. Mol Cell. 9:993–1004. 2002. View Article : Google Scholar : PubMed/NCBI
|
33.
|
Dawson CW, Port RJ and Young LS: The role
of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the
pathogenesis of nasopharyngeal carcinoma (NPC). Semin Cancer Biol.
22:144–153. 2012. View Article : Google Scholar : PubMed/NCBI
|
34.
|
Tulalamba W and Janvilisri T:
Nasopharyngeal carcinoma signaling pathway: an update on molecular
biomarkers. Int J Cell Biol. 2012:5946812012. View Article : Google Scholar : PubMed/NCBI
|
35.
|
Mei YP, Zhou JM, Wang Y, et al: Silencing
of LMP1 induces cell cycle arrest and enhances chemosensitivity
through inhibition of AKT signaling pathway in EBV-positive
nasopharyngeal carcinoma cells. Cell Cycle. 6:1379–1385. 2007.
View Article : Google Scholar
|
36.
|
Korotayev K, Chaussepied M and Ginsberg D:
ERK activation is regulated by E2F1 and is essential for
E2F1-induced S phase entry. Cell Signal. 20:1221–1226. 2008.
View Article : Google Scholar : PubMed/NCBI
|
37.
|
Deng L, Yang J, Zhao XR, et al: Cells in
G2/M phase increased in human nasopharyngeal carcinoma cell line by
EBV-LMP1 through activation of NF-kappaB and AP-1. Cell Res.
13:187–194. 2003. View Article : Google Scholar : PubMed/NCBI
|
38.
|
Zhao XR, Gu HH, Weng XX, Yi W, Deng XY and
Cao Y: The primary study on expression and function of D-type
cyclins in nasopharyngeal carcinoma cell lines. Sheng Wu Hua Xue Yu
Sheng Wu Wu Li Xue Bao (Shanghai). 32:192–196. 2000.PubMed/NCBI
|
39.
|
Liu DX and Greene LA: Neuronal apoptosis
at the G1/S cell cycle checkpoint. Cell Tissue Res. 305:217–228.
2001. View Article : Google Scholar : PubMed/NCBI
|
40.
|
Tao D, Wu J, Feng Y, Qin J, Hu J and Gong
J: New method for the analysis of cell cycle-specific apoptosis.
Cytometry A. 57:70–74. 2004. View Article : Google Scholar : PubMed/NCBI
|
41.
|
Agarwal C, Dhanalakshmi S, Singh RP and
Agarwal R: Inositol hexaphosphate inhibits growth and induces G1
arrest and apoptotic death of androgen-dependent human prostate
carcinoma LNCaP cells. Neoplasia. 6:646–659. 2004. View Article : Google Scholar
|
42.
|
Ma X, Yang L, Xiao L, et al:
Down-regulation of EBV-LMP1 radio-sensitizes nasal pharyngeal
carcinoma cells via NF-kappaB regulated ATM expression. PLoS One.
6:e246472011. View Article : Google Scholar : PubMed/NCBI
|